Tubau-Juni, N., Hontecillas, R., Leber, A., Maturavongsadit, P., Chauhan, J., & Bassaganya-Riera, J. (2021). First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis. Nature Portfolio.
Style de citation Chicago (17e éd.)Tubau-Juni, Nuria, Raquel Hontecillas, Andrew Leber, Panita Maturavongsadit, Jyoti Chauhan, et Josep Bassaganya-Riera. First-in-class Topical Therapeutic Omilancor Ameliorates Disease Severity and Inflammation Through Activation of LANCL2 Pathway in Psoriasis. Nature Portfolio, 2021.
Style de citation MLA (8e éd.)Tubau-Juni, Nuria, et al. First-in-class Topical Therapeutic Omilancor Ameliorates Disease Severity and Inflammation Through Activation of LANCL2 Pathway in Psoriasis. Nature Portfolio, 2021.